BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/14/2025 10:33:26 AM | Browse: 143 | Download: 726
 |
Received |
|
2024-07-05 07:31 |
|
Peer-Review Started |
|
2024-07-05 07:31 |
|
First Decision by Editorial Office Director |
|
2024-10-20 10:45 |
|
Return for Revision |
|
2024-10-20 10:45 |
|
Revised |
|
2024-11-02 15:19 |
|
Publication Fee Transferred |
|
2024-11-08 01:55 |
|
Second Decision by Editor |
|
2024-12-16 02:47 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-12-16 07:52 |
|
Articles in Press |
|
2024-12-16 07:52 |
|
Edit the Manuscript by Language Editor |
|
2024-12-28 21:53 |
|
Typeset the Manuscript |
|
2025-01-22 03:32 |
|
Publish the Manuscript Online |
|
2025-02-14 10:33 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Significance of monitoring imatinib plasma concentration in second-line treatment decisions for c-kit11 gene-mutated gastrointestinal stromal tumors
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Hai-Tao Li, Yun-Yun Du, Zhen Huang, Jin-Jin Li and Jun Zhang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jun Zhang, Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing 400016, China. zjun2323@sina.cn |
| Key Words |
Gastrointestinal stromal tumor; C-kit 11; Imatinib; Plasma concentration; Second-line treatment |
| Core Tip |
This study showed that increasing the dosage of imatinib (IM) for patients with advanced gastrointestinal stromal tumors harboring c-kit exon 11 mutation who experienced failure of first-line IM treatment can prolong overall survival when the plasma concentration is < 1100 ng/mL; and switching to another tyrosine kinase inhibitor can improve the disease control rate and achieve longer progression-free survival when the plasma concentration is ≥ 1100 ng/mL. Therefore, IM plasma concentration may guide the decision-making for second-line treatment. |
| Publish Date |
2025-02-14 10:33 |
| Citation |
Li HT, Du YY, Huang Z, Li JJ, Zhang J. Significance of monitoring imatinib plasma concentration in second-line treatment decisions for c-kit11 gene-mutated gastrointestinal stromal tumors. World J Gastrointest Oncol 2025; 17(3): 98746 |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i3/98746.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i3.98746 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
